-

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September:

  • 21st Annual Wells Fargo Healthcare Conference on Wednesday, September 9, 2026 at 11:00 a.m. EDT
  • Cantor Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 9:45 a.m. EDT
  • Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026 at 12:20 p.m. EDT

The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte
Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X, and Instagram.

Contacts

Incyte Contacts
Media

media@incyte.com

Investors
ir@incyte.com

Incyte

NASDAQ:INCY

Release Summary
Incyte to Present at Upcoming Investor Conferences
Release Versions
$Cashtags

Contacts

Incyte Contacts
Media

media@incyte.com

Investors
ir@incyte.com

Social Media Profiles
More News From Incyte

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...

Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

WILMINGTON, Del.--(BUSINESS WIRE)--Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the EU for Adults with Moderate Atopic Dermatitis...

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates...
Back to Newsroom